MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, OVID had -$7,804K decrease in cash & cash equivalents over the period. -$12,872K in free cash flow.

Cash Flow Overview

Change in Cash
-$7,804K
Free Cash flow
-$12,872K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-12,158 -14,919
Change in fair value of royalty monetization liability
0 0
Unrealized loss (gain) on equity investments
0 -66
Change in accrued interest and accretion of discount on marketable securities
-111 -322
Stock-based compensation expense
1,109 2,503
Depreciation and amortization expense
16 240
Noncash operating lease expense
300 582
Change in lease liability
-337 -657
Prepaid expenses and other current assets
-522 878
Accounts payable
-2,240 760
Accrued expenses
27 -3,147
Deferred revenue
0 718
Net cash used in operating activities
-12,872 -15,054
Purchase of marketable securities
4,947 9,845
Sales/maturities of marketable securities
10,000 27,000
Purchases of property and equipment
0 0
Software development and other costs
0 0
Net cash provided by investing activities
5,053 17,155
Proceeds from exercise of options and purchases from employee stock purchase plan
15 13
Net cash provided by financing activities
15 13
Net decrease in cash, cash equivalents and restricted cash
-7,804 2,114
Cash and cash equivalents at beginning of period
28,232 -
Cash and cash equivalents at end of period
22,542 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Inc. (OVID)